ClinicalTrials.gg
CompletedNCT03238079Updated Jun 30, 2026Results posted

Study of PlasmaCap IG in Adults and Children With PIDD

A Phase 3 interventional study of 10% IGIV in Primary Immune Deficiency Diseases (PIDD), sponsored by Evolve Biologics. Completed at 12 sites in 2 countries. Open to participants aged 2 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-06-30.

Sponsored by Evolve Biologics · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
63
Allocation
Not applicable
Ages
2 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases — 2 open to participants now, 4 under way, 4 of them phase 3. Immunoglobulins, Intravenous · Primary Immunodeficiency Diseases.

Enrollment
3rd of 26
63 · median 45
Started
2017
with 1 other
Phase 3
18 of 27
2 open now
Registered
21st of 27
by date
Lead sponsor
1 of 27
Evolve Biologics

Among the 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases, this one is the 3rd largest by enrollment of the 26 interventional ones that give a count, is one of 2 that started in 2017, is one of 18 in phase 3, and was the 21st registered.

Primary Immunodeficiency Diseases

211 studies on the registry are indexed under Primary Immunodeficiency Diseases; 51 are open to participants now.

Browse Primary Immunodeficiency Diseases studies →

Open to participants now

2 of the 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases are open now. Recruiting first, the newest first:

All 2 open studies →

About Immunoglobulins, Intravenous

Immunoglobulins, Intravenous: first FDA approval 1944 (Baygam, Gamastan S/D), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 35 Primary Immunodeficiency Diseases studies recruiting now, 12 (34%) set no upper age limit and 10 (29%) stop at 75 or younger; 28 take children under 18; 11 take healthy volunteers.

This study: 2 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the efficacy, safety, tolerability, and pharmacokinetic profile of the investigational medicinal product (IMP) and to determine, on the basis of historical control data, how it compares with other 10% intravenous immunoglobulin (IGIV) products currently licensed in North America for the treatment of subjects with primary immune deficiency diseases (PIDD).

03

Conditions studied

  • Primary Immune Deficiency Diseases (PIDD)
04

Who can participate

Ages eligible
2 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has a confirmed clinical diagnosis of a PIDD, which requires treatment with IGIV:
  • Subject/guardian has provided written (and assent, as applicable).
  • Subject is between the ages of 2 and 70 years.
  • Subject has received regular IGIV therapy at 21- or 28-day (±4 days) intervals for at least three consecutive months at a dose between 300-900 mg/kg/month prior to Screening or;
  • Subject has received commercial SCIG at a dose of 300-900 mg/kg/month on any dosing schedule for at least 12 consecutive weeks prior to Screening. Subjects on SCIG must have received and tolerated IGIV treatment prior to SCIG treatment.
  • Subject has a documented trough of ≥500 mg/dL in the 6 months prior to screening.
  • Females of must be willing to use an effective form of (eg, oral contraceptives) for the duration of the study, per IRB/REB guidelines.
  • Subject agrees to comply with the requirements of the protocol.

Exclusion criteria

Exclusion Criteria:

  • Subject has secondary immunodeficiency.
  • Subject has history of thrombotic events, such as deep vein thrombosis, myocardial infarction, cerebrovascular accident, pulmonary embolism, etc within the year prior to screening.
  • Subject has had an immune globulin associated arterial or venous thrombotic/thromboembolic event (TEE) within 7 days of infusion or a TEE that is not associated with an immune globulin within one year of screening.
  • Subject has received blood products (except for IGIV, SCIG, or albumin) within 6 months of screening.
  • Subject has anemia (≤8.5 g/dL).
  • Subject has levels of (ALT) or aspartate aminotransferase (AST) >3.0 times the (ULN).
  • Subject has severe neutropenia (≤1000 neutrophils per mm3).
  • Subject is receiving other or immunomodulatory drugs or chemotherapy.
  • Subject is taking or has taken within the four weeks prior to screening prednisone at ≥0.15 mg/kg/day for more than 10 days.
  • Subject has ever had a severe anaphylactic reaction to a blood or IgG product.
  • Subject has lymphoid , leukemia, or any other history of malignancy within the past five years, except squamous cell or basal cell carcinoma of the skin (not melanoma).
  • Subject has hypoalbuminemia, protein-losing enteropathy, or proteinuria greater than 300 mg/24 hours except for subjects with documented orthostatic proteinuria.
  • Subject has immunoglobulin A (IgA) deficiency with known antibodies to IgA.
  • Female who is pregnant, breastfeeding, or planning a pregnancy during the course of the study (women who become pregnant during the study will be withdrawn from the study).
  • Any condition that is likely to interfere with evaluation of IMP or satisfactory conduct of the trial in the PI's opinion.
  • Subjects who may not be compliant or have a history of non-compliance in the opinion of the PI.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
63 participants (actual)

Study arms

  • Experimental
    Open-Label 10% IGIV

    IMP will be administered every 21 or 28 days in accordance with the subject's weekly regimen at screening for a period of 12 months. Subjects on a 21-day regimen will receive approximately 17 infusions, and subjects on a 28-day regimen will receive approximately 13 infusions. The starting dose will be the previous IGIV dose or a dose calculated from the previous SCIG dose up to a maximum of 900 mg/kg/mo.

    Biological: 10% IGIV

Interventions

  • Biological10% IGIV

    300-900 mg/kg

    Also known as: Human Immunoglobulin

06

What researchers measure

Primary outcomes

  1. Mean Acute Serious Bacterial Infection (SBI) Rate

    The primary efficacy endpoint was the rate of acute SBI (pneumonia, bacteremia and septicemia, osteomyelitis/septic arthritis, bacterial meningitis, visceral abscess) per participant during the 12-month study observation period

    Time frame: 1 year

Secondary outcomes

  1. Immunoglobulin G (IgG) Trough Concentration

    The average serum total IgG trough concentration

    Time frame: Up to 1 year per participant

  2. Days Unable to Perform Daily Activities

    The number of days out of work/school/daycare or unable to perform normal daily activities due to infections

    Time frame: Up to 1 year per participant

  3. Therapeutic IgG Levels

    Number of participants with maintenance of stable IgG levels

    Time frame: Up to 1 year per participant

07

Results

Posted Jun 30, 2026

Participant flow

A total of 63 patients were enrolled between September 2017 and August 2020 at 13 sites across the United States and Canada.

Participant flow — Overall Study
MilestoneAdultsPediatrics
Started4815
Completed4215
Not completed60

Outcome measures

PrimaryMean Acute Serious Bacterial Infection (SBI) Rate

The primary efficacy endpoint was the rate of acute SBI (pneumonia, bacteremia and septicemia, osteomyelitis/septic arthritis, bacterial meningitis, visceral abscess) per participant during the 12-month study observation period

Time frame:
1 year
Reported as:
Number · Percentage
Mean Acute Serious Bacterial Infection (SBI) Rate
PercentageAdultsPediatrics
Mean Acute Serious Bacterial Infection (SBI) Rate00
SecondaryImmunoglobulin G (IgG) Trough Concentration

The average serum total IgG trough concentration

Time frame:
Up to 1 year per participant
Reported as:
Mean · mg/mL
Immunoglobulin G (IgG) Trough Concentration
mg/mLAdultsPediatrics
Infusion 1 (Pre-dose)974.3 ± 175.6925.5 ± 239.4
Infusion 2977.8 ± 177.0951.0 ± 213.6
Infusion 3975.8 ± 204.9996.0 ± 212.0
Infusion 4963.1 ± 182.81041.7 ± 230.9
Infusion 5976.2 ± 194.81027.9 ± 217.3
Infusion 6951.9 ± 193.01071.0 ± 205.3
Infusion 7980.0 ± 185.11011.3 ± 209.4
Infusion 8967.5 ± 200.41039.6 ± 258.2
Infusion 9970.4 ± 200.71077.7 ± 236.3
Infusion 10992.6 ± 203.71047.3 ± 193.8
Infusion 11999.2 ± 197.31075.8 ± 230.4
Infusion 121016.0 ± 215.71054.1 ± 201.3
Infusion 131007.5 ± 189.51061.3 ± 241.1
Infusion 141090.1 ± 266.91198.9 ± 183.9
Infusion 151057.4 ± 223.51154.9 ± 223.4
Infusion 161092.4 ± 261.91117.3 ± 205.5
Infusion 171139.6 ± 241.51171.6 ± 230.1
Safety Follow-Up1010.8 ± 208.11110.1 ± 322.0
SecondaryDays Unable to Perform Daily Activities

The number of days out of work/school/daycare or unable to perform normal daily activities due to infections

Time frame:
Up to 1 year per participant
Reported as:
Mean · Days
Days Unable to Perform Daily Activities
DaysAdultsPediatrics
Days Unable to Perform Daily Activities6.0 ± 9.68.1 ± 11.6
SecondaryTherapeutic IgG Levels

Number of participants with maintenance of stable IgG levels

Time frame:
Up to 1 year per participant
Reported as:
Count of participants · Participants
Therapeutic IgG Levels
ParticipantsAdultsPediatrics
Therapeutic IgG Levels4815

Adverse events

Collected over From enrollment to end of follow-up at 1 year. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Adults0/48 (0%)4/48 (8.3%)44/48 (91.7%)
Pediatrics0/15 (0%)0/15 (0%)15/15 (100%)
Most frequent serious events
Most frequent serious events
EventAdultsPediatrics
PneumoniaInfections and infestations1/480/15
PyelonephritisInfections and infestations1/480/15
Viral infectionInfections and infestations1/480/15
Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/480/15
Most frequent other events
Showing 10 of 28
Most frequent other events
EventAdultsPediatrics
HeadacheNervous system disorders19/489/15
CoughRespiratory, thoracic and mediastinal disorders7/487/15
VomitingGastrointestinal disorders4/486/15
NauseaGastrointestinal disorders5/485/15
PyrexiaGeneral disorders7/485/15
NasopharyngitisInfections and infestations7/485/15
FatigueGeneral disorders10/484/15
Pain in extremityMusculoskeletal and connective tissue disorders5/484/15
Oropharyngeal painRespiratory, thoracic and mediastinal disorders6/484/15
Nasal congestionRespiratory, thoracic and mediastinal disorders2/484/15

Baseline characteristics

Includes the adult and pediatric populations

Age, Customized
Age, Customized(Years)AdultsPediatricsTotal
Age, Continuous49.4 ± 14.38.9 ± 4.439.8 ± 21.5
Sex: Female, Male
Sex: Female, Male(Participants)AdultsPediatricsTotal
Female27532
Male211031
Race (NIH/OMB)
Race (NIH/OMB)(Participants)AdultsPediatricsTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White481462
More than one race000
Unknown or Not Reported011
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)AdultsPediatricsTotal
Hispanic or Latino123
Not Hispanic or Latino471360
Unknown or Not Reported000
Body Mass Index
Body Mass Index(kg/m2)AdultsPediatricsTotal
Mean30.14 ± 7.7225.54 ± 25.4129.03 ± 14.04
08

Study locations

12 sites
  • University of California
    Los Angeles, California 92697, United States
  • IMMUNOe Health & Research Centers
    Centennial, Colorado 80112, United States
  • University of South Florida
    Tampa, Florida 33620, United States
  • Allergy Associates of the Palm Beaches, P.A.
    West Palm Beach, Florida 33408, United States
  • Institute for Asthma and Allergy, PC
    Chevy Chase, Maryland 20815, United States
  • Optimed Research Ltd.
    Little Silver, New Jersey 07739, United States
  • Optimed Research LTD
    Columbus, Ohio 43235, United States
  • Allergy Partners of North Texas
    Dallas, Texas 75230, United States
  • AARA Research Center
    Dallas, Texas 75231, United States
  • AAICPA
    Irving, Texas 75063, United States
  • The Medical College of Wisconsin, Inc.
    Milwaukee, Wisconsin 53226, United States
  • CHU Ste-Justine
    Montreal, Quebec H3T 1C5, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2017 to primary completion in Aug 2020, 35 months.

Results were first posted in Jun 2026, 5 years 10 months after primary completion.

Of 25 phase 3 interventional studies under Primary Immunodeficiency Diseases, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 41. This study's 35 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2017
First posted
Aug 3, 2017
StartActual
Sep 5, 2017
Primary completionActual
Aug 25, 2020
CompletionActual
Aug 25, 2020
Results first posted
Jun 30, 2026
Last update
Jun 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03238079
Lead sponsor
Evolve Biologics
Responsible party
Sponsor
First posted
Aug 3, 2017
Start date
Sep 5, 2017
Primary completion
Aug 25, 2020
Completion
Aug 25, 2020
Results posted
Jun 30, 2026
Last update
Jun 30, 2026

Study contacts

Mark Krause
study director · Therapure Biopharma

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immunoglobulins, Intravenous

Start the discussion